Henry Gosebruch, Neumora CEO

Neu­mora's big neu­ro­science plans head to­ward the Nas­daq in sec­ond PhI­II biotech IPO pitch in 24 hours

The large­ly dor­mant biotech IPO mar­ket start­ed siz­zling Fri­day, with two Phase III drug de­vel­op­ers send­ing in their pitch­es for Nas­daq de­buts this fall …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.